Ramipril

Drug Profile

Ramipril

Alternative Names: Acuvil; Altace; Carasel; Delix; HOE 498; Hypren; Pramace; Quark; Ramace; Triatec; Tritace; Unipril; Vesdil

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer AstraZeneca; King Pharmaceuticals; Monarch Pharmaceuticals; Pfizer; Sanofi
  • Class Antihypertensives; Heart failure therapies; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension
  • Clinical Phase Unknown Ischaemic heart disorders
  • Discontinued Kidney disorders; Type 2 diabetes mellitus

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 27 Jul 2015 Sanofi in collaboration with Centre Hospitalier Universitaire de Saint Etienne terminates the PREFACE trial in Atrial fibrillation in France due to difficulty to include patients (NCT00736294)
  • 04 Mar 2015 Ramipril licensed to Valeant Canada in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top